Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Long

Showing results (501-510 of 703) with videos related to

Pageof 71
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 18, 2025
A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanomaAndrea Boutros, Amelia M Taylor, Isabel Li, et al.
Journal of Translational Medicine|September 5, 2022
Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation settingMathias Seviiri, Richard A Scolyer, D Timothy Bishop, et al.
European Journal of Cancer (Oxford, England : 1990)|October 10, 2022
Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective studyPatricio Serra-Bellver, Judith M Versluis, Honey K Oberoi, et al.
European Journal of Cancer (Oxford, England : 1990)|June 14, 2021
Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapiesSydney Ch'ng, Semra Uyulmaz, Matteo S Carlino, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2015
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanomaDirk Schadendorf, Mayur M Amonkar, Daniil Stroyakovskiy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2023
Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 TherapyHansol Lee, Angela L Ferguson, Camelia Quek, et al.
The Journal of Experimental Medicine|May 21, 2026
CSF1R-dependent CD169-positive macrophages locally constrain melanoma growth in the skinYuki Honda Keith, Emily Duchini, Xufeng Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus TrametinibJan C Brase, Robert F H Walter, Alexander Savchenko, et al.
Australian Journal of General Practice|May 29, 2020
Australian general practitioners' attitudes and knowledge of sentinel lymph node biopsy in melanoma managementCaroline G Watts, Andrea L Smith, Sam Robinson, et al.
The Lancet. Oncology|June 8, 2019
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF<sup>V600</sup> mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trialGeorgina V Long, Robyn P M Saw, Serigne Lo, et al.
Pageof 71

Showing results (501-510 of 703) with videos related to

Sort By:
Pageof 71
European Journal of Cancer (Oxford, England : 1990)|September 18, 2025
A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanomaAndrea Boutros, Amelia M Taylor, Isabel Li, et al.
Journal of Translational Medicine|September 5, 2022
Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation settingMathias Seviiri, Richard A Scolyer, D Timothy Bishop, et al.
European Journal of Cancer (Oxford, England : 1990)|October 10, 2022
Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective studyPatricio Serra-Bellver, Judith M Versluis, Honey K Oberoi, et al.
European Journal of Cancer (Oxford, England : 1990)|June 14, 2021
Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapiesSydney Ch'ng, Semra Uyulmaz, Matteo S Carlino, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2015
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanomaDirk Schadendorf, Mayur M Amonkar, Daniil Stroyakovskiy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2023
Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 TherapyHansol Lee, Angela L Ferguson, Camelia Quek, et al.
The Journal of Experimental Medicine|May 21, 2026
CSF1R-dependent CD169-positive macrophages locally constrain melanoma growth in the skinYuki Honda Keith, Emily Duchini, Xufeng Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus TrametinibJan C Brase, Robert F H Walter, Alexander Savchenko, et al.
Australian Journal of General Practice|May 29, 2020
Australian general practitioners' attitudes and knowledge of sentinel lymph node biopsy in melanoma managementCaroline G Watts, Andrea L Smith, Sam Robinson, et al.
The Lancet. Oncology|June 8, 2019
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF<sup>V600</sup> mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trialGeorgina V Long, Robyn P M Saw, Serigne Lo, et al.
Pageof 71